scholarly journals Hepatitis C Infection Among Pregnant Women in British Columbia: Reported Prevalence and Critical Appraisal of Current Prenatal Screening Methods

2011 ◽  
Vol 102 (2) ◽  
pp. 98-102 ◽  
Author(s):  
Audrey Blasig ◽  
◽  
Emily C. Wagner ◽  
David Pi ◽  
Mark Bigham ◽  
...  
2019 ◽  
Vol 12 (1) ◽  
Author(s):  
Rulin Dai ◽  
Yang Yu ◽  
Qi Xi ◽  
Xiaonan Hu ◽  
Haibo Zhu ◽  
...  

Abstract Background Several different technologies are used for prenatal screening procedures and genetic diagnostic technologies. We aimed to investigate the rates of chromosomal abnormalities in cases with different abnormal prenatal indications and to determine the relationships between fetal chromosomal abnormalities and indicators of prenatal abnormalities in Northeast China. Methods We evaluated 4953 16- to 23-week singleton gestation cases using amniocentesis and a total of 3583 participants received serological screening. Fetal chromosomal analyses were performed for all samples using fluorescence in situ hybridization and karyotyping. Results Among these samples, 204 (4.12%) had fetal chromosomal abnormalities. A total of 3583 participants received serological screening, among whom 102 (2.85%) exhibited positive results. A total of 309 participants had ultrasonography; 42 (13.6%) of these had abnormalities. Among 97 participants who had non-invasive prenatal testing (NIPT), 59 (61%) had positive results. Among 1265 participants with advanced maternal age, 78 (6.2%) had abnormal results. Conclusion The serological screening and NIPT that were included in the prenatal screening methods all had false positive and false negative rates. Although they are both prenatal screening techniques, maternal serum screening cannot be replaced by NIPT. The pregnancy women should accept NIPT in a qualified prenatal diagnostic center. We recommend that pregnant women at high or critical risk undergoing prenatal screening should confirm the fetal karyotype through amniocentesis. Moreover, if women receive a positive result via NIPT, they should not have a pregnancy termination without undergoing further prenatal diagnosis.


2014 ◽  
Vol 36 (6) ◽  
pp. 482-490 ◽  
Author(s):  
Margot Kuo ◽  
Deborah M. Money ◽  
Maria Alvarez ◽  
Jane A. Buxton ◽  
Mel Krajden ◽  
...  

PLoS ONE ◽  
2020 ◽  
Vol 15 (12) ◽  
pp. e0244575
Author(s):  
Margo E. Pearce ◽  
Amanda Yu ◽  
Maria Alvarez ◽  
Sofia R. Bartlett ◽  
Mawuena Binka ◽  
...  

Objective Current guidelines in British Columbia recommend prenatal screening for hepatitis C antibodies (anti-HCV) if risk factors are present. We aimed to estimate frequency of prenatal anti-HCV testing, new diagnoses, repeated and follow-up testing among BC women. Methods BC Centre for Disease Control Public Health Laboratory data estimated the number of BC women (assigned female at birth or unknown sex) aged 13–49 who received routine prenatal serological screening (HIV, hepatitis B, syphilis and rubella) from 2008–2019. Anti-HCV tests ordered the same day as routine prenatal screens were considered prenatal anti-HCV tests. Assessment of follow-up was based on HCV RNA and/or genotype testing within one year of new prenatal anti-HCV diagnoses. Results In 2019, 55,202 routine prenatal screens were carried out for 50,392 BC women. Prenatal anti-HCV tests increased significantly, from 19.6% (9,704/49,515) in 2008 to 54.6% (27,516/50,392) in 2019 (p<0.001). New prenatal anti-HCV diagnoses (HCV positive diagnoses at first test or seroconversions) declined from 14.3% in 2008 to 10.1% in 2019. The proportion of women with new prenatal anti-HCV diagnoses that were a result of a first HCV test declined from 0.3% (29/9,701) in 2008 to 0.03% (8/27,500) in 2019. For women known to be anti-HCV positive at the time of prenatal screening, the proportion who had a prenatal anti-HCV test increased from 35.6% in 2008 to 50.8% in 2019. Conclusion Prenatal anti-HCV testing increased substantially over the study period. However, new HCV diagnoses remained relatively stable, suggesting that a considerable proportion of BC women with low or no risk are being screened as part of prenatal care. The vast majority of women with new HCV diagnoses receive appropriate follow-up HCV RNA and genotype testing, which may indicate interest in HCV treatment. These findings contribute to the discussion around potential for prenatal anti-HCV screening in an effort to eliminate HCV.


2019 ◽  
Vol 28 (3) ◽  
pp. 313-318 ◽  
Author(s):  
Małgorzata Aniszewska ◽  
Maria Pokorska-Śpiewak ◽  
Barbara Kowalik-Mikołajewska ◽  
Magdalena Pluta ◽  
Magdalena Marczyńska

1997 ◽  
Vol 167 (9) ◽  
pp. 470-472 ◽  
Author(s):  
Jennifer J Garner ◽  
Matt Gaughwin ◽  
Jane Dodding ◽  
Kristyn Willson

Sign in / Sign up

Export Citation Format

Share Document